Browse > Article
http://dx.doi.org/10.5090/kjtcs.2015.48.3.193

Surgical Treatment for Non-Small Cell Lung Cancer in Patients on Hemodialysis due to Chronic Kidney Disease: Clinical Outcome and Intermediate-Term Results  

Park, Byung Jo (Department of Thoracic and Cardiovascular Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine)
Shin, Sumin (Department of Thoracic and Cardiovascular Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine)
Kim, Hong Kwan (Department of Thoracic and Cardiovascular Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine)
Choi, Yong Soo (Department of Thoracic and Cardiovascular Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine)
Kim, Jhingook (Department of Thoracic and Cardiovascular Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine)
Shim, Young Mog (Department of Thoracic and Cardiovascular Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine)
Publication Information
Journal of Chest Surgery / v.48, no.3, 2015 , pp. 193-198 More about this Journal
Abstract
Background: Patients on dialysis undergoing surgery belong to a high-risk group. Only a few studies have evaluated the outcome of major thoracic surgical procedures in dialysis patients. We evaluated the outcomes of pulmonary resection for non-small cell lung cancer (NSCLC) in patients on hemodialysis (HD). Methods: Between 2008 and 2013, seven patients on HD underwent pulmonary resection for NSCLC at our institution. We retrospectively reviewed their surgical outcomes and prognoses. Results: The median duration of HD before surgery was 55.0 months. Five patients underwent lobectomy and two patients underwent wedge resection. Postoperative morbidity occurred in three patients, including pulmonary edema combined with pneumonia, cerebral infarction, and delirium. There were no instances of in-hospital mortality, although one patient died of intracranial bleeding 15 days after discharge. During follow-up, three patients (one patient with pathologic stage IIB NSCLC and two patients with pathologic stage IIIA NSCLC) experienced recurrence and died as a result of the progression of the cancer, while the remaining three patients (with pathologic stage I NSCLC) are alive with no evidence of disease. Conclusion: Surgery for NSCLC in HD patients can be performed with acceptable perioperative morbidity. Good medium-term survival in patients with pathologic stage I NSCLC can also be expected. Pulmonary resection seems to be the proper treatment option for dialysis patients with stage I NSCLC.
Keywords
Dialysis; Renal dialysis; Pulmonary surgical procedures; Thoracic surgery; Lung neoplasms;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Obuchi T, Hamanaka W, Yoshida Y, et al. Clinical outcome after pulmonary resection for lung cancer patients on hemodialysis. Ann Thorac Surg 2009;88:1745-8.   DOI
2 Patel P, Henry LL, Ganti AK, Potti A. Clinical course of lung cancer in patients with chronic kidney disease. Lung Cancer 2004;43:297-300.   DOI
3 Pinson CW, Schuman ES, Gross GF, Schuman TA, Hayes JF. Surgery in long-term dialysis patients. Experience with more than 300 cases. Am J Surg 1986;151:567-71.   DOI
4 Tsuchida M, Yamato Y, Aoki T, et al. Complications associated with pulmonary resection in lung cancer patients on dialysis. Ann Thorac Surg 2001;71:435-8.   DOI
5 American Cancer Society. Cancer facts and figures 2014. Atlanta (GA): American Cancer Society; 2014.
6 Bunn PA Jr. Early-stage non-small-cell lung cancer: current perspectives in combined-modality therapy. Clin Lung Cancer 2004;6:85-98.   DOI
7 Ozel L, Krand O, Ozel MS, et al. Elective and emergency surgery in chronic hemodialysis patients. Ren Fail 2011;33:672-6.   DOI
8 Schreiber S, Korzets A, Powsner E, Wolloch Y. Surgery in chronic dialysis patients. Isr J Med Sci 1995;31:479-83.
9 Chen KS, Huang CC, Leu ML, Deng P, Lo SK. Hemostatic and fibrinolytic response to desmopressin in uremic patients. Blood Purif 1997;15:84-91.   DOI
10 Lee HK, Kim YJ, Jeong JU, Park JS, Chi HS, Kim SB. Desmopressin improves platelet dysfunction measured by in vitro closure time in uremic patients. Nephron Clin Pract 2010;114:c248-52.   DOI
11 Diaz-Ricart M, Etebanell E, Cases A, et al. Erythropoietin improves signaling through tyrosine phosphorylation in platelets from uremic patients. Thromb Haemost 1999;82:1312-7.   DOI
12 Kearney DJ, Lee TH, Reilly JJ, DeCamp MM, Sugarbaker DJ. Assessment of operative risk in patients undergoing lung resection. Importance of predicted pulmonary function. Chest 1994;105:753-9.   DOI
13 Eneman JD, Philips GK. Cancer management in patients with end-stage renal disease. Oncology (Williston Park) 2005;19:1199-212.
14 Fabris F, Cordiano I, Randi ML, et al. Effect of human recombinant erythropoietin on bleeding time, platelet number and function in children with end-stage renal disease maintained by haemodialysis. Pediatr Nephrol 1991;5:225-8.   DOI
15 Ciriaco P, Casiraghi M, Melloni G, et al. Pulmonary resection for non-small-cell lung cancer in patients on hemodialysis: clinical outcome and long-term results. World J Surg 2005;29:1516-9.   DOI